Molecular You Secures $5M to Advance Predictive Health
Slice of Healthcare Team
08/29/2025
Key highlights
- $5M Series A financing led by Voloridge Health, with participation from Dynamic Leap
- 250+ biomarkers analyzed via a single blood test for whole-body insights
- Nationwide expansion in Canada and the U.S., with clinical and D2C availability
- Next-gen assay in development to measure over 800 biomarkers
- Proven early detection, including stage 1 pancreatic cancer in a symptom-free patient
Source: PR Newswire
Notable Quotes
“ We plan to use this capital to grow our customer base across both consumer and clinical channels in North America, while also continuing to expand the platform's analysis and predictive capabilities. ”
Jim Kean, CEO at Molecular You
“ Fragmented measurement of individual biomarkers cannot offer the same predictive capabilities as our platform, which sees the body as a whole. ”
Dr. Murdoc Khaleghi, Chief Medical Officer at Molecular You
“ Molecular You is advancing a critical shift in healthcare, from reactive treatment to predictive and preventive care, through biomarker science and real-world clinical impact. ”
David Vogel, CEO at Voloridge Health
Why This Matters
Molecular You's $5 million Series A funding marks a significant milestone in the shift toward predictive and preventive healthcare. By offering a comprehensive biomarker-based assessment from a single blood test, the company empowers both individuals and healthcare providers to detect health risks earlier, tailor interventions, and reduce dependence on symptom-based diagnostics. With the development of a next-generation assay and growing partnerships across North America, Molecular You is poised to set new standards in precision medicine and longevity care.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
